Inventor · disambiguated record
Piotr H. Karpinski
Also filed as: KARPINSKI PIOTR · KARPINSKI PIOTR H · KARPINSKI PIOTR HENRYK
24 granted patents·24 pending applications·679 citations·filing 1992–2024
96Inventor score
Top patents by PatentIndex Score
48 records- 0198US5560932AMicroprecipitation of nanoparticulate pharmaceutical agentsNANO SYS LLC·Filed 1995·Granted Oct 1, 1996·350 cites·55 claims
- 0296US8877938B2Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2006·Granted Nov 4, 2014·44 cites·14 claims
- 0394US8163904B2Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-BenzamideMANLEY PAUL W·Filed 2006·Granted Apr 24, 2012·32 cites·4 claims
- 0493US5401492AWater insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agentsSTERLING WINTHROP INC·Filed 1992·Granted Mar 28, 1995·168 cites·7 claims
- 0592US8389537B2Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideMANLEY PAUL W·Filed 2012·Granted Mar 5, 2013·17 cites·2 claims
- 0691US9624192B2Carbamate/urea derivativesAUBERSON YVES·Filed 2016·Granted Apr 18, 2017·11 cites·20 claims
- 0791US2025339395A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2024·Application pending·0 cites
- 0888US8580806B2Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideNOVARTIS AG·Filed 2013·Granted Nov 12, 2013·9 cites·2 claims
- 0987US9034874B2Carbamate/urea derivativesAUBERSON YVES·Filed 2013·Granted May 19, 2015·12 cites·20 claims
- 1086US9388134B2Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2014·Granted Jul 12, 2016·5 cites·15 claims
- 1186US9163005B2Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideNOVARTIS AG·Filed 2013·Granted Oct 20, 2015·6 cites·1 claims
- 1284US11642329B2Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Granted May 9, 2023·0 cites·2 claims
- 1384US8486930B2SaltsDE LA CRUZ MARILYN·Filed 2009·Granted Jul 16, 2013·8 cites·20 claims
- 1484US2024239743A11-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, (e)-but-2-enedioic acidNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1583US2022257551A1Amorphous solid form of compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Application pending·0 cites
- 1682US9273026B2Carbamate/urea derivativesAUBERSON YVES·Filed 2015·Granted Mar 1, 2016·4 cites·24 claims
- 1781US11096918B2Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2019·Granted Aug 24, 2021·0 cites·2 claims
- 1879US2021361610A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2021·Application pending·0 cites
- 1977US9309229B2Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamineFENG LILI·Filed 2011·Granted Apr 12, 2016·3 cites·26 claims
- 2076US7989494B2Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamideNOVARTIS AG·Filed 2007·Granted Aug 2, 2011·3 cites·42 claims
- 2175US2023357142A91-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, (e)-but-2-enedioic acidNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2272US8697682B2SaltsDE LA CRUZ MARILYN·Filed 2013·Granted Apr 15, 2014·2 cites·20 claims
- 2372US8202998B2Salts of benzimidazolyl pyridyl ethers and formulations thereofGULLAPALLI RAMPURNA·Filed 2007·Granted Jun 19, 2012·2 cites·3 claims
- 2472US2019374498A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2572US2019374497A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2669US9802931B2Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursorsNOVARTIS AG·Filed 2016·Granted Oct 31, 2017·1 cites·8 claims
- 2769US2018344679A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2867US9365565B2Salts of aza-bicyclic di-aryl ethers and pharmaceuticals thereofMARTERER WOLFGANG·Filed 2012·Granted Jun 14, 2016·2 cites·16 claims
- 2966US2021323915A1Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acidNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3062US2016324821A1Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsFENG LILI·Filed 2016·Application pending·0 cites
- 3162US2012115840A1Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acidCISZEWSKI LECH·Filed 2009·Application pending·0 cites
- 3261US2014343087A1Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamideMANLEY PAUL W·Filed 2014·Application pending·0 cites
- 3358US10421755B2Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursorsNOVARTIS AG·Filed 2017·Granted Sep 24, 2019·0 cites·13 claims
- 3458US2018118678A1Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acidNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3556US2009197936A1Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamideNOVARTIS AG·Filed 2007·Application pending·0 cites
- 3654US2010093749A1CompoundsNOVARTIS AG·Filed 2008·Application pending·0 cites
- 3754US2014005162A1Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acidCISZEWSKI LECH·Filed 2013·Application pending·0 cites
- 3854US2017275264A1Carbamate/urea derivativesAUBERSON YVES·Filed 2017·Application pending·0 cites
- 3952US9181215B2Manufacturing process for pyrimidine derivativesDE LA CRUZ MARILYN·Filed 2011·Granted Nov 10, 2015·0 cites·13 claims
- 4050US8501785B2Salts of benzimidazolyl pyridyl ethers and formulations thereofGULLAPALLI RAMPURNA·Filed 2012·Granted Aug 6, 2013·0 cites·24 claims
- 4148US2011112308A1Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamideNOVARTIS AG·Filed 2011·Application pending·0 cites
- 4248US2015175536A1Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acidCISZEWSKI LECH·Filed 2015·Application pending·0 cites
- 4347US7977330B2Salts and crystal modifications thereofNOVARTIS AG·Filed 2007·Granted Jul 12, 2011·0 cites·15 claims
- 4446US2010286409A1Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamideNOVARTIS AG·Filed 2010·Application pending·0 cites
- 4545US2009131528A1SaltFENG LILI·Filed 2007·Application pending·0 cites
- 4643US2016175305A1Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamineFENG LILI·Filed 2016·Application pending·0 cites
- 4738US2008221336A1Pparalpha/Gamma Agonists and Processes of PreparingGARRETT CHRISTINE E·Filed 2006·Application pending·0 cites
- 4838US2012053184A1Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2, 5-di oneKARPINSKI PIOTR·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Piotr H. Karpinski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →